[1] Huttner A, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015 Sep;70(9):2456-64. DOI:
10.1093/jac/dkv147[2] Garau J. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:198-202. DOI:
10.1111/j.1469-0691.2007.01852.x[3] Linus Sandegren, et al. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother. 2008 Sep;62(3):495-503. DOI:
10.1093/jac/dkn222[4] Xiaodong Wang, et al. Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos. 2007 Feb;35(2):268-74. DOI:
10.1124/dmd.106.011684
